is a glp-1 a peptide Medications – Community Education Dual and Triple Gut Peptide

For certain patients, quieter hunger signals allow more effective participation in therapy and the development of healthier coping strategies

Eligible Medicare patients living with obesity will have access to Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults living with obesity with known heart disease, a claim only Wegovy can make Novo Nordisk's participation in the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ -- The Medicare GLP-1 Bridge will provide eligible Medicare beneficiaries living with obesity access to Wegovy (semaglutide) injection and tablets for a $50 monthly copay , beginning July 1, 2026, per yesterday's announcement from the Centers for Medicare & Medicaid Services (CMS)

For weight management, at least 5% weight loss from baseline after 12 weeks on maintenance dose is required to continue treatment

Day-After Dinner Day-after dinner should still respect your appetite